MX2012002830A - Formulacion estable de hialuronano/esteroide. - Google Patents

Formulacion estable de hialuronano/esteroide.

Info

Publication number
MX2012002830A
MX2012002830A MX2012002830A MX2012002830A MX2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A MX 2012002830 A MX2012002830 A MX 2012002830A
Authority
MX
Mexico
Prior art keywords
stable
composition
steroid formulation
stable hyaluronan
hyaluronan
Prior art date
Application number
MX2012002830A
Other languages
English (en)
Spanish (es)
Inventor
Grace Chang
Elizabeth Voschin
Li-Ping Yu
Eugene Skrabut
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2012002830A publication Critical patent/MX2012002830A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2012002830A 2009-09-10 2010-08-10 Formulacion estable de hialuronano/esteroide. MX2012002830A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/556,869 US8273725B2 (en) 2009-09-10 2009-09-10 Stable hyaluronan/steroid formulation
PCT/US2010/044975 WO2011031402A1 (en) 2009-09-10 2010-08-10 Stable hyaluronan/steroid formulation

Publications (1)

Publication Number Publication Date
MX2012002830A true MX2012002830A (es) 2012-04-10

Family

ID=43648224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002830A MX2012002830A (es) 2009-09-10 2010-08-10 Formulacion estable de hialuronano/esteroide.

Country Status (8)

Country Link
US (2) US8273725B2 (https=)
EP (2) EP2475251B1 (https=)
JP (2) JP6121717B2 (https=)
CN (1) CN102573468B (https=)
AR (1) AR078281A1 (https=)
BR (1) BR112012005423B1 (https=)
MX (1) MX2012002830A (https=)
WO (1) WO2011031402A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633978A1 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects
CN102573941B (zh) 2009-07-30 2014-10-29 卡比兰生物外科公司 改性透明质酸聚合物组合物和相关的方法
ES2537411T3 (es) 2011-04-20 2015-06-08 Carbylan Therapeutics, Inc. Composiciones formadoras de gel in situ
TWI424007B (zh) 2011-12-22 2014-01-21 Ind Tech Res Inst 使膠體交聯的方法與藉由此方法形成之經交聯的膠體
WO2014110454A1 (en) * 2013-01-11 2014-07-17 Carbylan Biosurgery, Inc. Stabilized compositions comprising hyaluronic acid
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
KR20190038368A (ko) 2017-09-29 2019-04-08 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법
CN118021719A (zh) * 2022-11-11 2024-05-14 北京华视诺维医疗科技有限公司 一种曲安奈德组合物及其制备方法
WO2025068242A1 (en) * 2023-09-25 2025-04-03 Hyamedix Dexamethasone delivery system

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
SE442820B (sv) 1984-06-08 1986-02-03 Pharmacia Ab Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (sv) 1985-03-01 1986-09-02 Pharmacia Ab Format alster och forfarande for dess framstellning
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4866050A (en) 1988-04-27 1989-09-12 Ben Amoz Daniel Ultrasonic transdermal application of steroid compositions
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5234914A (en) 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5207983A (en) * 1992-01-29 1993-05-04 Sterling Winthrop Inc. Method of terminal steam sterilization
IT1260154B (it) 1992-07-03 1996-03-28 Lanfranco Callegaro Acido ialuronico e suoi derivati in polimeri interpenetranti (ipn)
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5621093A (en) 1995-06-06 1997-04-15 Anika Research, Inc. Steam-sterilizing solid hyaluronic acid
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
TW577758B (en) 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6066292A (en) 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
US6521223B1 (en) 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE392907T1 (de) 2000-07-28 2008-05-15 Anika Therapeutics Inc Bioabsorbierbare kompositmaterialien aus derivatisierter hyaluronsäure
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
BR0115584A (pt) 2000-11-24 2003-09-23 Breath Ltd Esterilização de produtos farmacêuticos
EP1401508A1 (en) 2001-06-29 2004-03-31 Biovitrum Ab Process for bulk autoclaving
US20050222081A1 (en) 2002-04-17 2005-10-06 Gianolio Diego A Cross-linked hyaluronate compounds
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
CA2550718C (en) * 2003-12-30 2013-11-05 Genzyme Corporation Cohesive gels from cross-linked hyaluronan and/or hylan, their preparation and use
WO2005066214A1 (ja) 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
US20060094700A1 (en) 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
CA2633957A1 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
CN101677957A (zh) 2007-02-05 2010-03-24 卡比兰生物外科公司 用于递送生物活性试剂的聚合物制剂
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20100331257A1 (en) 2008-01-31 2010-12-30 Sofradim Production Preparation of terminally-sterilized collagen that is soluble at neutral ph

Also Published As

Publication number Publication date
BR112012005423B1 (pt) 2022-09-13
CN102573468B (zh) 2015-05-20
EP2475251A4 (en) 2012-10-24
WO2011031402A1 (en) 2011-03-17
BR112012005423A2 (pt) 2017-07-04
EP3622820B1 (en) 2026-02-18
JP2013504570A (ja) 2013-02-07
JP2015172095A (ja) 2015-10-01
EP3622820A1 (en) 2020-03-18
US20110059918A1 (en) 2011-03-10
CN102573468A (zh) 2012-07-11
US8680073B2 (en) 2014-03-25
US20120316131A1 (en) 2012-12-13
EP2475251B1 (en) 2019-07-17
JP6121717B2 (ja) 2017-04-26
AR078281A1 (es) 2011-10-26
EP2475251A1 (en) 2012-07-18
US8273725B2 (en) 2012-09-25

Similar Documents

Publication Publication Date Title
MX2012002830A (es) Formulacion estable de hialuronano/esteroide.
EA201001555A1 (ru) Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
MX2017010131A (es) Composiciones farmaceuticas para terapia combinada.
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
EP3699172A3 (en) Novel lipids and compositions for the delivery of therapeutics
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
BR112012022774A2 (pt) Composição sólida compreendendo primeira e segunda dispersões sólidas amorfas
BRPI0905369C8 (pt) composição farmacêutica, uso da composição farmacêutica e kit compartimentado
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BR112012033391A8 (pt) kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova.
BR112014016550A8 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
BR112012017136A2 (pt) Composição farmacêutica compreendendo 3-beta- hidróxi-5-alfa-pregnan-20-ona com propriedades de armazenamento e solubidade aperfeiçoadas.
EA200970851A1 (ru) Еженедельное введение ингибиторов дипептидилпептидазы
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112013006362A2 (pt) uso de compostos profármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para reduzir a pressão intraocular, composição farmacêutica e artigo de fabricação
BR112014016661A2 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112013019394A2 (pt) uso de um agente
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112017011476A2 (pt) composição baseada em aminoácidos para recuperação de fibroelastina em tecidos conjuntivos dérmicos e uso

Legal Events

Date Code Title Description
FG Grant or registration